


SEP 05 2007

Appl'n No.: 10/542,287
Case No.: 21321P
Page No.: 2**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Previously presented) A compound of Formula I: ~~or a pharmaceutically acceptable salt thereof~~



I

or a pharmaceutically acceptable salt thereof, wherein:

~~wherein~~ R¹ is selected from the group consisting of H, Cl, F, and C₁₋₄alkyl, where C₁₋₄alkyl is optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R² is selected from the group consisting of H, Cl, F, C₁₋₄alkyl, OC₁₋₄alkyl, and -S(O)₂CH₃, where C₁₋₄alkyl and OC₁₋₄alkyl are optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, F, Cl, C₁₋₃alkyl, and -OC₁₋₃alkyl, where C₁₋₃alkyl and -OC₁₋₃alkyl are optionally substituted with 1-3 halogens independently selected from F and Cl;

X and Y are each independently selected from the group consisting of O, S, SO, and SO₂; and

n represents an integer selected from 1, 2, 3, and 4.

Claim 2 (Previously presented) The compound according to Claim 1 wherein R² is selected from H, F, -OC₁₋₃ alkyl, and -S(O)₂CH₃, where -OC₁₋₃ alkyl is optionally substituted with 1-3 F atoms.

Appl'n No.: 10/542,287
Case No.: 21321P
Page No.: 3

Claim 3 (Previously presented) The compound according to Claim 1, wherein

R¹ is selected from Cl and n-propyl;

R² is selected from H and F; and

R³, R⁴ and R⁵ are H.

Claim 4 (Previously presented) The compound according to Claim 1, wherein R² is -OCH₂CH₃ or -OCH₂CF₃.

Claim 5 (Previously presented) The compound according to Claim 1, wherein R⁵ is H; and R³ and R⁴ are each independently selected from H, F, CH₃, CF₃, -OCH₃, -OCF₃, -OCH₂CH₃ and -OCH₂CF₃.

Claim 6 (Previously presented) The compound according to Claim 1, wherein X and Y are each independently selected from O and S.

Claim 7 (Previously presented) The compound according to Claim 1, wherein X and Y are each O.

Claim 8 (Previously presented) The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is meta to the sulfonamide group.

Claim 9 (Previously presented) The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is para to the sulfonamide group.

Claim 10 (Previously presented) The compound according to Claim 1, wherein n is 1-3.

Claim 11 (Previously presented) The compound according to Claim 1, wherein n is 3 or 4.


Claim 12 (Previously presented) The compound according to Claim 1, wherein X and Y are O; n is an integer selected from 1-3; R³, R⁴ and R⁵ are H; R¹ is selected from n-propyl and Cl; and R² is selected from H, F, and -S(O)₂CH₃.

Claim 13 (Previously presented) The compound according to Claim 1, wherein R¹ is C₂₋₃ alkyl, which is optionally substituted with 1-3 F atoms.

Appl'n No.: 10/542,287
Case No.: 21321P
Page No.: 4

Claim 14 (Previously presented) The compound according to Claim 1, wherein R¹ is n-propyl.

Claim 15 (Previously presented) The compound which is selected from the compounds below, or a pharmaceutically acceptable salt thereof:



Claim 16 (Original) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

Appl'n No.: 10/542,287
Case No.: 21321P
Page No.: 5

Claim 17 (Original) A method for treating hyperglycemia in a mammalian or human patient having non-insulin dependent (Type 2) diabetes mellitus which comprises administering to said patient a therapeutically effective amount of a compound of Claim 1.

Claims 18-33 (Canceled)